Pfizer Licenses Three Autoimmune Treatments From Starna
The deal gives Pfizer exclusive rights outside Greater China to develop, manufacture and commercialize three early-stage experimental autoimmune therapies.
Updated on Nov. 18, 2026 in Biotech

Pfizer has entered a licensing agreement with Starna Therapeutics covering three early-stage autoimmune treatments, giving Pfizer exclusive rights outside Greater China. Starna receives a $330 million upfront payment and is eligible for up to $2.3 billion more tied to development and commercial milestones.
Why it matters
The agreement lets Pfizer expand its pipeline into in vivo CAR-T therapies for autoimmune diseases without developing the programs from scratch. For Starna, the deal provides substantial near-term funding while keeping it positioned to earn royalties on any approved products.
The three programs are experimental in vivo CAR-T therapies for autoimmune diseases, with finished drug products for initial clinical trials to be manufactured at Pfizer's U.S. facilities. The agreement does not disclose the specific molecular targets, clinical-stage timelines, or preclinical efficacy data for the treatments.
The players
Pfizer
Pfizer is a large U.S.-based multinational pharmaceutical company known for its vaccines, oncology drugs and broad research pipeline.
Starna Therapeutics
Starna Therapeutics is a biotechnology company developing experimental in vivo CAR-T therapies for autoimmune diseases.
The details
Under the agreement, Pfizer gains exclusive rights outside Greater China to develop, manufacture and commercialize the three treatments, and it will lead clinical development of the programs in that territory. Pfizer also holds an option to extend its territorial rights to include Greater China.
Timeline
November 18, 2026: Pfizer announced the licensing agreement with Starna Therapeutics.
The Tech Race
The agreement places Pfizer in the emerging race to move CAR-T cell therapy beyond oncology into autoimmune disease, where in vivo approaches seek to avoid the complex manufacturing required by today's ex vivo cell therapies. It follows a pattern of large pharmaceutical companies licensing early-stage cell therapy assets from smaller biotechs to build out their pipelines.
For patients with autoimmune conditions, this deal does not change treatment options in the near term, since the programs remain in early development with no approved products. Any eventual therapy would require clinical trials and regulatory review before becoming available.
The takeaway
Licensing deals like this one show how large drugmakers are turning to smaller biotechs for early-stage technology, with payments structured around milestones that may or may not be reached. Readers should treat headline deal values as contingent, since most of the figure depends on future success.
Further reading
For more on the science behind these therapies, explore our Biotech coverage.



